Long-term effects of protease-inhibitor-based combination therapy on CD4 T-cell recovery in HIV-1-infected children and adolescents

Lancet

Volumn 362, Issue 9401, 2003, Pages 2045-2051

  Soh, Chang Heok ^a   Oleske, James M ^b   Brady, Michael T ^c   Spector, Stephen A ^d   Borkowsky, William ^e   Burchett, Sandra K ^f   Foca, Marc D ^g   Handelsman, Edward ^h   Jiménez, Eleanor ⁱ   Dankner, Wayne M ^j   Hughes, Michael D ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^c NATIONWIDE CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g Och Spine at New York Presbyterian Hospitals   (United States)

^h Children's Medical Center of Brooklyn   (United States)

ⁱ San Juan City Hospital   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 9144258622     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)15098-2     Document Type: Article

References (39)

1. Guidelines for the use of antiretroviral agents in pediatric HIV infection. June 25, 2003. http://www.hivatis.org (accessed Dec 9, 2003).
2. Sharland M., di Zub G.C., Ramos J.T., Blanche S., Gibb D.M. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. HIV Med. 3:2002;215-226.
3. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings: guidelines for a public health approach: executive summary. WHO: Geneva, 2002.
4. Gulick R., Mellors J., Havlir D., et al. Simultaneous vs sequential initiation of therapy with indinavir, zidovudine and lamivudine for HIV-1 infection: 100 week follow-up. JAMA. 280:1998;35-41.
5. Li T.S., Tubiana R., Katlama C., Calvez V., Ait Mohand H., Autran B. Long-lasting recovery of CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 351:1998;1682-1686.
6. Hammer S.M., Squires K.E., Hughes M.D., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infections and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 337:1997;725-733.
7. Ledergerber B., Egger M., Opravil M., et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 353:1999;863-868.
8. Deeks S.G., Barbour J.D., Martin J.N., Swanson M.S., Grant R.M. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 181:2000;946-953.
9. Kaufmann D., Pantaleo G., Sudre P., Telenti A. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 351:1998;723-724.
10. Kline M.W., Fletcher C.V., Harris A.T., et al. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. J Pediatr. 132:1998;543-546.
11. Melvin A.J., Mohan K.M., Arcuino L.A., Edelstein R.E., Frenkel L.M. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J. 16:1997;968-974.
12. Mueller B.U., Sleasman J., Nelson RP Jr, et al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection. Pediatrics. 102:1998;101-109.
13. Nachman S.A., Stanley K., Yogev R., et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. JAMA. 283:2000;492-498.
14. Rutstein R.M., Feingold A., Meislich D., Word B., Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS. 11:1997;F107-F111.
15. Wiznia A., Stanley K., Krogstad P., et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial. AIDS Res Hum Retroviruses. 16:2000;1113-1121.
16. European Collaborative Study. Age-related standards for T lymphocyte subsets based on uninfected children born to human immunodeficiency virus 1-infected women. Pediatr Infect Dis J 1992; 11: 1018-1026.
17. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the PACTG P1009 Study. J Allergy Clin Immunol (in press).
18. Gortmaker S.L., Hughes M., Cervia J., et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 345:2001;1522-1528.
19. Buchacz K., Cervia J.S., Lindsey J.C., et al. Impact of protease inhibitor-containing combination antiretroviral therapies on height and weight growth in HIV-infected children. Pediatrics. 108:2001;e72.
20. CDC. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR Morb Mortal Wkly Rep 1994; 43: 1-10.
21. Brookmeyer R., Crowley J. A confidence interval for the median survival time. Biometrics. 38:1982;29-41.
22. Laird N.M., Ware J.H. Random-effects models for longitudinal data. Biometrics. 38:1982;963-974.
23. Lin H-M, Hughes M.D. Adjusting for regression to the mean when variables are normally distributed. Stat Methods Med Res. 6:1997;129-146.
24. Nikolic-Djokic D., Essajee S., Rigaud M., et al. Immunoreconstitution in children receiving highly active antiretroviral therapy depends on the CD4% at baseline. J Infect Dis. 185:2002;290-298.
25. de Martino M., Tovo P.A., Balducci M., et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. JAMA. 284:2000;190-197.
26. Schneider M., Borleffs J., Stolk R., Jaspers C.A., Hoepelman A.I. Discontinuation of prophylaxis for Pneumocytis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet. 353:1999;201-203.
27. Furrer H., Telenti A., Rossi M., Lederberger B. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. AIDS. 14:2000;1409-1412.
28. Pontesilli O., Kerkhof-Garde S., Notermans D.W., et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis. 180:1999;76-86.
29. Blankson J.N., Gallant J.E., Siliciano R.F. Proliferative responses to human immunodeficiency virus type 1 (HIV-1) antigens in HIV-1-infected patients with immune reconstitution. J Infect Dis. 183:2001;657-661.
30. Lange C.G., Valdez H., Medvik K., Asaad R., Lederman M.M. CD4+ T-lymphocyte nadir and the effect of highly active antiretroviral therapy on phenotypic and functional immune restoration in HIV-1 infection. Clin Immun. 102:2002;154-161.
31. Tasker S.A., Wallace M.R., Rubins J.B., Paxton W.B., O'Brien J., Janoff E.N. Reimmunization with 23-valent pneumococcal vaccine for patients infected with human immunodeficiency virus type 1: clinical, immunologic, and virologic responses. Clin Infect Dis. 34:2002;813-821.
32. Essajee S.M., Kim M., Gonzalez C., et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1-infected children. AIDS. 13:1999;2523-2532.
33. Zhang L., Lewin S.R., Markowitz M., et al. Measuring recent thymic emigrants in blood of normal and HIV-1-infected individuals before and after effective therapy. J Exp Med. 190:1999;725-732.
34. Vigano A., Vella S., Saresella M., et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS. 14:2000;251-261.
35. van Dyke R.B., Lee S., Johnson G.M., et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 109:2002;e61.
36. Barroga C.F., Raskino C., Fangon M.C., et al. The CCR5Δ32 allele slows disease progression of human immunodeficiency virus-1-infected children receiving antiretroviral treatment. J Infect Dis. 182:2000;413-419.
37. Fellay J., Boubaker B., Bernasconi E., et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet. 358:2001;1322-1327.
38. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. July 14, 2003. http://www.AIDSinfo.nih.gov (accessed Dec 9, 2003).
39. Arpadi S.M., Cuff P.A., Horlick M., Wang J., Kotler D.P. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4-positive-lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr. 27:2001;30-34.